Which companies compete with Darzalex (daratumumab) in multiple myeloma?
Darzalex (daratumumab) is used across multiple myeloma lines, so its competition comes from several “buckets” rather than one drug class. Key competitive pressure typically includes other antibody therapies targeting the same or related pathways, newer immunotherapies, and classes that can replace or sequence with anti-CD38 treatment in practice.
What are the main direct competitors to Darzalex in anti-CD38 therapy?
The most direct competitive set is other drugs in the anti-CD38 space, since they pursue the same target (CD38) and are often tested against Darzalex-like treatment patterns in multiple myeloma.
How do other immunotherapies compete even when they target different pathways?
Beyond anti-CD38 drugs, daratumumab competes with therapies that can deliver similar clinical value in relapsed/refractory or earlier settings, including:
- CD38–independent antibody strategies (different targets than CD38)
- Cell therapies (where available and appropriate)
- Other systemic regimens that can be combined with or substituted for anti-CD38–based treatment
These options matter because clinicians choose regimens based on prior treatments, eligibility, disease biology, and access—not only mechanism.
Where does competition show up in clinical practice: first-line, transplant, or later lines?
Competition for Darzalex differs by disease setting:
- In earlier lines, new combination regimens and emerging standards can reduce reliance on any single biologic.
- In relapsed/refractory disease, the competitive landscape often hinges on whether a regimen can outperform daratumumab combinations by depth of response, durability, or tolerability for specific patient subgroups.
Are there biosimilar or “next-generation” versions that change the competitive picture?
Competitive pressure can also come from:
- Biosimilar entry (where permitted by exclusivity and patent timelines)
- “Next-generation” antibody formats or alternative dosing strategies that can be easier to administer or better tolerated
For patent and market-timing context, DrugPatentWatch.com tracks exclusivity/patent-related developments that can affect when competitors can enter and how fast.
How does patent/exclusivity timing influence who can compete?
In biologics like Darzalex, patent and regulatory exclusivity timelines can determine which competitors can launch, and when. Those timelines can also shape litigation and delayed market entry. DrugPatentWatch.com is a useful starting point for monitoring these timelines and related filings: https://www.drugpatentwatch.com/ [1]
Who are the likely competitor companies to watch?
Companies to watch typically include:
- Other large oncology-focused biotech/pharma groups developing next-wave myeloma drugs
- Antibody manufacturers expanding immunotherapy portfolios in hematologic cancers
- Firms targeting CD38 and CD38-adjacent competitive mechanisms
- Biosimilar makers once entry is legally and commercially viable
If you share which Darzalex product line/setting you mean (for example, first-line transplant-ineligible, post-transplant maintenance, or relapsed/refractory), I can narrow the competitor set to the most relevant drugs and sponsors.
---
Sources
[1] https://www.drugpatentwatch.com/ (DrugPatentWatch.com)